Details
Stereochemistry | ACHIRAL |
Molecular Formula | Mg |
Molecular Weight | 24.3051 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[MgH4]
InChI
InChIKey=RSHAOIXHUHAZPM-UHFFFAOYSA-N
InChI=1S/Mg.2H
Molecular Formula | Mg |
Molecular Weight | 24.3051 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttp://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.drugs.com/ppa/magnesium-chloride.htmldoi: 10.1081/SCC-120022479https://www.ncbi.nlm.nih.gov/pubmed/351265https://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/dosage/magnesium-lactate.htmlCurator's Comment:: description was created based on several sources, including:
http://drugpamphlet.blogspot.ru/2012/04/epimag.html | http://noillen.bitballoon.com/nutritional-suppleme5/magnesium-citrate-pr4451.html | http://www.webmd.com/drugs/2/drug-522-2202/magnesium-citrate/details
Sources: DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttp://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.drugs.com/ppa/magnesium-chloride.htmldoi: 10.1081/SCC-120022479https://www.ncbi.nlm.nih.gov/pubmed/351265https://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/dosage/magnesium-lactate.html
Curator's Comment:: description was created based on several sources, including:
http://drugpamphlet.blogspot.ru/2012/04/epimag.html | http://noillen.bitballoon.com/nutritional-suppleme5/magnesium-citrate-pr4451.html | http://www.webmd.com/drugs/2/drug-522-2202/magnesium-citrate/details
Magnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency.
CNS Activity
Sources: Vink, R., Mihai Nechifor, M. (2011) 'Magnesium in the Central Nervous System', p.139 Retrieved from https://books.google.ru/books?id=GW0oExaZ7hQCDOI: 10.1002/0471238961.0218151310010311.a02https://www.drugs.com/mtm/magnesium-lactate.html | https://www.ncbi.nlm.nih.gov/pubmed/27792736 | https://www.ncbi.nlm.nih.gov/pubmed/7669506
Curator's Comment:: Magnesium Chloride
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment:: Ulex, a Swedish geologist, is generally credited with introduction of the term struvite in1845
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001508 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12225296 |
|||
Target ID: GO:0010960 |
|||
Target ID: GO:0033609 |
|||
Target ID: GO:0010960 |
|||
Target ID: P05109 Gene ID: 6279.0 Gene Symbol: S100A8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8061680 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date7.9038723E11 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date7.9038723E11 |
|||
Diagnostic | ColPrep Kit Approved UseINDICATIONS AND USAGE
ColPrep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults Launch Date1.48279683E12 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date7.9038723E11 |
|||
Curative | MagMin Approved UseMagnesium aspartate (MagMin) is indicated for patients with documented hypomagnesaemia. |
|||
Curative | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Curative | Magnesium Chloride Approved UseMagnesium Chloride injection is indicated as an electrolyte replenisher in magnesium deficiencies |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Primary | EPIMAG Approved UseMagnesium citrate is indicated in cases of oxaluria, to prevent recurrence of calcium oxalate kidney stones. |
|||
Primary | EPIMAG Approved UseUsed to relief of occasional constipation (irregularity). |
|||
Curative | Magnesium Citrate Approved UseMagnesium citrate is indicated to supports magnesium nutritional adequacy. |
|||
Curative | Unknown Approved UseMagnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency. |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of manganese, calcium, magnesium and lithium on the ouabain-induced seizure. | 1977 |
|
[Magnesium--an alternative in treatment resistant tachyarrhythmias]. | 1977 May 30 |
|
Serum calcium and magnesium levels in schizophrenia. II. Possible relationship to extrapyramidal symptoms. | 1979 Nov |
|
Symptomatic hypercalcaemia precipitated by magnesium therapy. | 1985 Jan |
|
Regulation of membrane histamine H1-receptor binding sites by guanine nucleotides, mono- and divalent cations. | 1986 Apr |
|
Metal: ATP characteristics of insulin- and epidermal growth factor-stimulated phosphorylation in detergent extracts of rat liver plasma membranes. | 1986 Sep |
|
Decreased intracellular free magnesium in erythrocytes of spontaneously hypertensive rats. | 1987 Mar 30 |
|
A comparison of two digestion procedures for the determination of selenium in biological material. | 1987 Oct |
|
Fluorimetry of selenium in body fluids after digestion with nitric acid, magnesium nitrate hexahydrate, and hydrochloric acid. | 1988 Sep |
|
Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. | 1988 Sep 1 |
|
Effect of magnesium diet in gentamicin-induced acute renal failure in rats. | 1989 |
|
Polylysine specifically activates the insulin-dependent insulin receptor protein kinase. | 1989 Jun 15 |
|
[Arrhythmogenic effect of flecainide--treatment with i.v. magnesium]. | 1989 Sep |
|
Cocaine-induced cerebral vascular damage can be ameliorated by Mg2+ in rat brain. | 1990 Feb 5 |
|
Role of magnesium in cardiac tachyarrhythmias. | 1990 Jun 19 |
|
['Cardiac ballet' with and without amiodarone]. | 1993 Jan 13 |
|
Overexpressed protein kinase C-delta and -epsilon subtypes in NIH 3T3 cells exhibit differential subcellular localization and differential regulation of sodium-dependent phosphate uptake. | 1994 Feb 18 |
|
Cocaine-induced cerebrovasospasm and its possible mechanism of action. | 1994 Mar |
|
Differential modulation of alpha 3 beta 2 and alpha 3 beta 4 neuronal nicotinic receptors expressed in Xenopus oocytes by flufenamic acid and niflumic acid. | 1995 Mar |
|
Effects of felbamate on muscarinic and metabotropic-glutamate agonist-mediated responses and magnesium-free or 4-aminopyridine-induced epileptiform activity in guinea pig olfactory cortex neurons in vitro. | 1996 Jun |
|
Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. | 1999 Jul 15 |
|
Some magnesium salts and a mixture of magnesium and calcium salts accelerate skin barrier recovery. | 1999 Oct |
|
Trifluoromethanesulfonic anhydride-promoted alpha-bromination of ketones with grignard reagent or magnesium bromide. | 2000 Dec |
|
Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate induced hypertension in rats. | 2000 Jul |
|
An efficient chiral moderator prepared from inexpensive (+)-3-carene: synthesis of the HIV-1 non-nucleoside reverse transcriptase inhibitor DPC 963. | 2000 Oct 5 |
|
Magnesium bromide mediated highly diastereoselective heterogeneous hydrogenation of olefins. | 2002 Apr 18 |
|
Synthesis of a non-heme template for attaching four peptides: an approach to artificial iron(II)-containing peroxidases. | 2004 Jan 23 |
|
Formation of formal disilene fluoride adducts. | 2008 Dec 24 |
|
Inhaled magnesium fluoride reverse bronchospasma. | 2010 |
|
Magnesium imide: synthesis and structure determination of an unconventional alkaline earth imide from decomposition of magnesium amide. | 2011 Feb 7 |
|
C-H functionalization polycondensation of chlorothiophenes in the presence of nickel catalyst with stoichiometric or catalytically generated magnesium amide. | 2011 Jun 29 |
|
Tris(oxazolinyl)boratomagnesium-catalyzed cross-dehydrocoupling of organosilanes with amines, hydrazine, and ammonia. | 2011 Oct 26 |
|
Increased zinc and manganese in parallel with neurodegeneration, synaptic protein changes and activation of Akt/GSK3 signaling in ovine CLN6 neuronal ceroid lipofuscinosis. | 2013 |
|
Fluorescence lifetime analysis and effect of magnesium ions on binding of NADH to human aldehyde dehydrogenase 1. | 2013 Feb 25 |
|
Catalytic contribution of threonine 244 in human ALDH2. | 2013 Feb 25 |
|
Altered biometal homeostasis is associated with CLN6 mRNA loss in mouse neuronal ceroid lipofuscinosis. | 2013 Jun 15 |
|
Assessment of infantile mineral imbalances in autism spectrum disorders (ASDs). | 2013 Nov 11 |
|
Effects of three kinds of organic acids on phosphorus recovery by magnesium ammonium phosphate (MAP) crystallization from synthetic swine wastewater. | 2014 Apr |
|
Precipitation of amorphous magnesium ammonium phosphate: is it a precursor for staghorn stones? | 2014 Jun |
|
Evaluation of enantiomeric purity of magnesium-L-aspartate dihydrate. | 2015 Jan |
|
Assessment of pulmonary toxicity of MgO nanoparticles in rats. | 2015 Mar |
|
Preparation and optimization of a drug delivery system based on berberine chloride-immobilized MgAl hydrotalcite. | 2016 Jun 15 |
|
No effect of multivitamin supplementation on central blood pressure in healthy older people: A randomized controlled trial. | 2016 Mar |
|
MgF2-coated porous magnesium/alumina scaffolds with improved strength, corrosion resistance, and biological performance for biomedical applications. | 2016 May |
|
A Soft Grip: Magnesium Complexes with a Phosphine-Modified Phosphonium Diylidic Lewis Base. | 2016 Nov 21 |
|
Nano-layered magnesium fluoride reservoirs on biomaterial surfaces strengthen polymorphonuclear leukocyte resistance to bacterial pathogens. | 2017 Jan 5 |
|
Fast sono assisted ferrofluid mediated silver super - Adsorption over magnesium ferrite-copper sulfide chalcogenide with the aid of multivariate optimization. | 2017 Jul |
|
Magnesium amide catalyzed selective hydroboration of esters. | 2017 Mar 27 |
|
Effect of power ultrasound on crystallization characteristics of magnesium ammonium phosphate. | 2017 May |
|
Antenatal Exposure to Magnesium Sulfate and Spontaneous Intestinal Perforation and Necrotizing Enterocolitis in Extremely Preterm Neonates. | 2017 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: DOI: 10.2903/j.efsa.2008.883
Curator's Comment:: Rats: MgF2 dissolved in acetic acid (Mg=0.08 mM, F=0.084 mM) was delivered in the aerosol form
https://www.ncbi.nlm.nih.gov/pubmed/20647692
The daily exposure levels were equivalent to approximately 240 mg of magnesium and 2600 mg of L-aspartic acid for adults.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 13:02:54 UTC 2021
by
admin
on
Sat Jun 26 13:02:54 UTC 2021
|
Record UNII |
I38ZP9992A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
29365-4
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
17236-1
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
29364-7
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
57998-7
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
13474-2
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
29912-3
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
2596-5
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
2597-3
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
87469-3
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
2595-7
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
35252-6
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
57367-5
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
55938-5
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
24447-5
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
56956-6
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
42616-3
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
35249-2
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
32024-2
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
WHO-ATC |
A12CC01
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
2594-0
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
32329-5
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
20872-8
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
14824-7
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
57368-3
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
2598-1
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
WHO-ATC |
B05XA11
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
54919-6
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
2599-9
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LIVERTOX |
579
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
29911-5
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
44336-6
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
10880-3
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
23891-5
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
26746-8
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
50873-9
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
11554-3
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
58995-2
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
19124-7
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
74696-6
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
33950-7
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
27210-4
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
49007-8
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
87470-1
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
19123-9
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
26708-8
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
2601-3
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
17235-3
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
9478-9
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
23892-3
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
2593-2
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
30536-7
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
21377-7
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
35250-0
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
18368-1
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
27122-1
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
CFR |
21 CFR 102.23
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
30922-9
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
25954-9
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
16172-9
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
18369-9
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
52911-5
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
17237-9
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
LOINC |
27255-9
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
||
|
DSLD |
82 (Number of products:11063)
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
654
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
PRIMARY | |||
|
I38ZP9992A
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
PRIMARY | |||
|
5462224
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
PRIMARY | |||
|
DB14513
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
PRIMARY | |||
|
7439-95-4
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
PRIMARY | |||
|
M6987
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
PRIMARY | Merck Index | ||
|
231-104-6
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
PRIMARY | |||
|
7439-95-4
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
PRIMARY | |||
|
21 CFR 862.1495
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
PRIMARY | |||
|
C68264
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
PRIMARY | |||
|
D008274
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
PRIMARY | |||
|
6574
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
PRIMARY | RxNorm | ||
|
SUB14407MIG
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
PRIMARY | |||
|
C1505
Created by
admin on Sat Jun 26 13:02:54 UTC 2021 , Edited by admin on Sat Jun 26 13:02:54 UTC 2021
|
CONCEPT | Dietary Supplement |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Nutritional value per 100 g (3.5 oz) - 21 mg (6%)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |